Last reviewed · How we verify
Bromfenac 0.09% eyedrops
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye. Used for Postoperative inflammation and pain following ocular surgery, Ocular inflammation associated with allergic conjunctivitis or other inflammatory eye conditions.
At a glance
| Generic name | Bromfenac 0.09% eyedrops |
|---|---|
| Sponsor | Università degli Studi di Brescia |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
As a topical NSAID eyedrop, bromfenac penetrates ocular tissues and suppresses COX-1 and COX-2 enzymes, thereby decreasing prostaglandin production. This reduces inflammatory mediators responsible for pain, swelling, and inflammation following ocular surgery or in inflammatory eye conditions. The 0.09% formulation is designed for optimal ocular bioavailability and anti-inflammatory efficacy.
Approved indications
- Postoperative inflammation and pain following ocular surgery
- Ocular inflammation associated with allergic conjunctivitis or other inflammatory eye conditions
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Corneal erosion or keratitis
- Headache
Key clinical trials
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Bromfenac Versus Dexamethasone After Cataract Surgery (PHASE4)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection. (PHASE4)
- Control of Pain in Intravitreal Injections Using Topical NSAIDs (PHASE4)
- Comparison of Treatments in Diabetic Macular Edema (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |